Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4408) 4408
Book Review (923) 923
Publication (224) 224
Newsletter (109) 109
Newspaper Article (86) 86
Magazine Article (34) 34
Book / eBook (30) 30
Book Chapter (20) 20
Conference Proceeding (13) 13
Dissertation (2) 2
Paper (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (3727) 3727
humans (2974) 2974
animals (2423) 2423
male (1736) 1736
venom (1549) 1549
female (1368) 1368
adult (970) 970
middle aged (895) 895
pharmacology & pharmacy (656) 656
immunology (651) 651
allergy (629) 629
toxicology (597) 597
diabetes mellitus, type 2 - drug therapy (513) 513
aged (506) 506
abridged index medicus (489) 489
venoms - therapeutic use (484) 484
mice (482) 482
peptides - therapeutic use (470) 470
adolescent (457) 457
immunotherapy (432) 432
antivenins - therapeutic use (429) 429
treatment outcome (420) 420
hypoglycemic agents - therapeutic use (395) 395
exenatide (390) 390
child (389) 389
research (379) 379
bites and stings (375) 375
care and treatment (370) 370
venoms - adverse effects (366) 366
analysis (359) 359
snakes (340) 340
type 2 diabetes (315) 315
peptides - adverse effects (312) 312
peptides (310) 310
endocrinology & metabolism (307) 307
venoms - administration & dosage (304) 304
rats (303) 303
peptides - administration & dosage (300) 300
snake bites - therapy (297) 297
anaphylaxis (294) 294
health aspects (285) 285
antivenom (284) 284
diabetes (283) 283
medicine, general & internal (277) 277
hypoglycemic agents - adverse effects (268) 268
peptides - pharmacology (264) 264
glucagon-like peptide-1 (263) 263
envenomation (257) 257
hypoglycemic agents - administration & dosage (255) 255
glycemic control (254) 254
risk factors (250) 250
time factors (250) 250
bee venoms - adverse effects (243) 243
proteins (237) 237
medicine (228) 228
venoms - pharmacology (225) 225
safety (222) 222
allergies (220) 220
child, preschool (220) 220
insect bites and stings - immunology (214) 214
anaphylaxis - etiology (204) 204
dose-response relationship, drug (196) 196
drug therapy (196) 196
bees (194) 194
studies (191) 191
retrospective studies (190) 190
biochemistry & molecular biology (189) 189
glucose (189) 189
young adult (188) 188
efficacy (184) 184
liraglutide (184) 184
antivenins - adverse effects (179) 179
snake bites - complications (179) 179
bee venoms - immunology (177) 177
allergens - immunology (174) 174
drug administration schedule (170) 170
bee venom (169) 169
diabetes mellitus, type 2 - blood (169) 169
insect bites and stings - complications (167) 167
hypersensitivity (165) 165
biological products (164) 164
wasp venoms - adverse effects (162) 162
double-blind (161) 161
exendin-4 (161) 161
insulin (161) 161
diagnosis (160) 160
hymenoptera (160) 160
metformin (160) 160
therapy (160) 160
toxins (160) 160
clinical trials (158) 158
glucagon-like peptide 1 - analogs & derivatives (158) 158
internal medicine (153) 153
children (152) 152
medical research (151) 151
venoms (151) 151
snake bites (150) 150
complex mixtures (149) 149
patients (148) 148
allergens (147) 147
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (18) 18
Royal Ontario Museum - Stacks (8) 8
UTL at Downsview - May be requested (4) 4
UofT at Mississauga - Stacks (3) 3
Architecture Landscape (Shore + Moffat) - Stacks (1) 1
Earth Sciences (Noranda) - Missing (1) 1
Royal Ontario Museum - Reference (1) 1
Scarborough Hospital - General (1) 1
UofT at Scarborough - May be requested in 6-10 wks (1) 1
UofT at Scarborough - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4418) 4418
French (71) 71
German (68) 68
Polish (24) 24
Spanish (22) 22
Russian (13) 13
Portuguese (12) 12
Japanese (9) 9
Swedish (8) 8
Danish (7) 7
Korean (7) 7
Chinese (6) 6
Norwegian (6) 6
Dutch (5) 5
Italian (5) 5
Turkish (3) 3
Czech (1) 1
Hebrew (1) 1
Hungarian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Novel biopesticide based on a spider venom peptide shows no adverse effects on honeybees
by Nakasu, Erich Y. T and Williamson, Sally M and Edwards, Martin G and Fitches, Elaine C and Gatehouse, John A and Wright, Geraldine A and Gatehouse, Angharad M. R
Proceedings of the Royal Society B: Biological Sciences, ISSN 0962-8452, 07/2014, Volume 281, Issue 1787, pp. 20140619 - 20140619
Evidence is accumulating that commonly used pesticides are linked to decline of pollinator populations; adverse effects of three neonicotinoids on bees have... 
Insecticidal fusion proteins | Pollinator decline | Honeybees | Biopesticide | V-hexatoxin-Hv1a | Snowdrop lectin (Galanthus nivalis agglutinin) | biopesticide | ω-hexatoxin-Hv1a | honeybees | insecticidal fusion proteins | snowdrop lectin (Galanthus nivalis agglutinin) | pollinator decline | BEE | APIS-MELLIFERA | MUSHROOM BODY | CURRENTS | COLONIES | EVOLUTIONARY BIOLOGY | NEONICOTINOID INSECTICIDES | CALCIUM-CHANNELS | MEMORY | omega-hexatoxin-Hv1a | BIOLOGY | ECOLOGY | EXPOSURE | BLOCKER | Mannose-Binding Lectins - metabolism | Spider Venoms - genetics | Mannose-Binding Lectins - toxicity | Learning - drug effects | Bees - growth & development | Recombinant Fusion Proteins - toxicity | Recombinant Fusion Proteins - metabolism | Calcium Channel Blockers - toxicity | Galanthus - chemistry | Animals | Insecticides - metabolism | Mannose-Binding Lectins - genetics | Plant Lectins - toxicity | Larva - drug effects | Spider Venoms - toxicity | Bees - drug effects | Recombinant Fusion Proteins - genetics | Spider Venoms - metabolism | Calcium Channel Blockers - metabolism | Plant Lectins - metabolism | Insecticides - toxicity | Plant Lectins - genetics | Index Medicus | 133 | 14 | s | 1001 | 31
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Anxiolytic activity and evaluation of potentially adverse effects of a bradykinin-related peptide isolated from a social wasp venom
by dos Anjos, Lilian Carneiro and Gomes, Flávia Maria Medeiros and do Couto, Lucianna Lopes and Mourão, Cecília Alves and Moreira, Karla Graziela and Silva, Luciano Paulino and Mortari, Márcia Renata
Life Sciences, ISSN 0024-3205, 03/2016, Volume 149, pp. 153 - 159
Anxiety disorders are major health problems in terms of costs stemming from sick leave, disabilities, healthcare and premature mortality. Despite the... 
Polybia paulista | Rotarod | Polisteskinin R | Open field | Elevated plus maze | Pathological anxiety | UNITED-STATES | MEDICINE, RESEARCH & EXPERIMENTAL | SYNAPTIC-TRANSMISSION | DRUG DISCOVERY | ANTICONVULSANT | TOXINS | ELEVATED PLUS-MAZE | INSECT CNS | PHARMACOLOGICAL-TREATMENT | PHARMACOLOGY & PHARMACY | ANXIETY DISORDERS | POLYBIA-OCCIDENTALIS | Drug Evaluation, Preclinical - methods | Bradykinin - therapeutic use | Wasp Venoms - therapeutic use | Rats, Wistar | Peptide Fragments - isolation & purification | Wasp Venoms - adverse effects | Bradykinin - adverse effects | Anxiety - psychology | Rats | Male | Anxiety - drug therapy | Anti-Anxiety Agents - isolation & purification | Wasp Venoms - isolation & purification | Animals | Bradykinin - isolation & purification | Anti-Anxiety Agents - adverse effects | Peptide Fragments - adverse effects | Peptide Fragments - therapeutic use | Anti-Anxiety Agents - therapeutic use | Complications and side effects | Nervous system diseases | Animal behavior | Bradykinin | Analysis | Venom | Physiological aspects | Anxiety | Wasps | Antianxiety agents | Medical care, Cost of | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1)
by Wysham, Carol and Blevins, Thomas and Arakaki, Richard and Colon, Gildred and Garcia, Pedro and Atisso, Charles and Kuhstoss, Debra and Lakshmanan, Mark
Diabetes Care, ISSN 0149-5992, 2014, Volume 37, Issue 8, pp. 2159 - 2167
OBJECTIVE To compare the efficacy and safety of dulaglutide, a once-weekly GLP-1 receptor agonist, with placebo and exenatide in type 2 diabetic patients. The... 
GLYCEMIC CONTROL | GLUCAGON-LIKE PEPTIDE-1 | EXENDIN-4 | SITAGLIPTIN | ENDOCRINOLOGY & METABOLISM | ANALOG LIRAGLUTIDE | OPEN-LABEL | LY2189265 | TREATED PATIENTS | Recombinant Fusion Proteins - adverse effects | Glucagon-Like Peptides - administration & dosage | Humans | Middle Aged | Male | Immunoglobulin Fc Fragments - administration & dosage | Thiazolidinediones - administration & dosage | Metformin - adverse effects | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Venoms - administration & dosage | Female | Metformin - administration & dosage | Drug Therapy, Combination | Glucagon-Like Peptides - analogs & derivatives | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Drug Administration Schedule | Venoms - adverse effects | Hypoglycemia - drug therapy | Thiazolidinediones - adverse effects | Blood Glucose - drug effects | Glucagon-Like Peptides - adverse effects | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Peptides - adverse effects | Type 2 diabetes | Care and treatment | Safety and security measures | Dosage and administration | Metformin | Comparative analysis | Exenatide | Clinical trials | Hemoglobin | Diabetes | Product safety | Drug dosages | Placebo effect | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Glucagonlike Peptide 1–Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus: A Population-Based Matched Case-Control Study
by Singh, Sonal and Chang, Hsien-Yen and Richards, Thomas M and Weiner, Jonathan P and Clark, Jeanne M and Segal, Jodi B
JAMA Internal Medicine, ISSN 2168-6106, 04/2013, Volume 173, Issue 7, pp. 534 - 539
IMPORTANCE Acute pancreatitis has significant morbidity and mortality. Previous studies have raised the possibility that glucagonlike peptide 1 (GLP-1)–based... 
METFORMIN | MEDICINE, GENERAL & INTERNAL | SAFETY | SITAGLIPTIN | EXENATIDE | COHORT | MODEL | COMPLICATIONS SEVERITY INDEX | Triazoles - adverse effects | Acute Disease | Pancreatitis - therapy | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Venoms - adverse effects | Humans | Middle Aged | Risk Factors | Logistic Models | Male | Hospitalization | Pancreatitis - chemically induced | Case-Control Studies | Adolescent | Pyrazines - adverse effects | Adult | Female | Sitagliptin Phosphate | Glucagon-Like Peptide 1 - adverse effects | Diabetes Mellitus, Type 2 - complications | Peptides - adverse effects | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies
by Elashoff, Michael and Matveyenko, Aleksey V and Gier, Belinda and Elashoff, Robert and Butler, Peter C
Gastroenterology, ISSN 0016-5085, 2011, Volume 141, Issue 1, pp. 150 - 156
Background & Aims Glucagon-like peptide-1−based therapy is gaining widespread use for type 2 diabetes, although there are concerns about risks for pancreatitis... 
Gastroenterology and Hepatology | Side Effect | Tumor | Pancreas | Toxicity | DRUG SAFETY | DIPEPTIDYL-PEPTIDASE-IV | EXENATIDE | SITAGLIPTIN | INCRETIN-BASED THERAPIES | RISK | SURVEILLANCE | ROSIGLITAZONE | GASTROENTEROLOGY & HEPATOLOGY | TYPE-2 DIABETES-MELLITUS | POLYPEPTIDE | Receptors, Glucagon - agonists | Triazoles - adverse effects | United States - epidemiology | Pancreatic Neoplasms - epidemiology | Risk Assessment | Adverse Drug Reaction Reporting Systems | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Pancreatitis - epidemiology | Venoms - adverse effects | Humans | Risk Factors | Thyroid Neoplasms - epidemiology | Pancreatitis - chemically induced | Diabetes Mellitus, Type 2 - epidemiology | Thyroid Neoplasms - chemically induced | Glucagon-Like Peptide-1 Receptor | Pyrazines - adverse effects | Pancreatic Neoplasms - chemically induced | Sitagliptin Phosphate | Diabetes Mellitus, Type 2 - drug therapy | Odds Ratio | Hypoglycemic Agents - adverse effects | Peptides - adverse effects | United States Food and Drug Administration | Type 2 diabetes | Care and treatment | Thyroid cancer | Peptides | Pancreatitis | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes
by Diamant, Michaela and Nauck, Michael A and Shaginian, Rimma and Malone, James K and Cleall, Simon and Reaney, Matthew and de Vries, Danielle and Hoogwerf, Byron J and MacConell, Leigh and Wolffenbuttel, Bruce H. R and 4B Study Grp and 4B Study Group
Diabetes Care, ISSN 0149-5992, 10/2014, Volume 37, Issue 10, pp. 2763 - 2773
OBJECTIVE: Mealtime insulin is commonly added to manage hyperglycemia in type 2 diabetes when basal insulin is insufficient. However, this complex regimen is... 
CONTROLLED-TRIAL | GLYCEMIC CONTROL | ORAL-THERAPY | COMBINATION THERAPY | PARALLEL-GROUP | EXENATIDE | ENDOCRINOLOGY & METABOLISM | OPEN-LABEL | TREATED PATIENTS | TREATMENT SATISFACTION | GETGOAL-L | Glycated Hemoglobin A - analysis | Hypoglycemia - epidemiology | Humans | Middle Aged | Body Weight - drug effects | Male | Hyperglycemia - drug therapy | Metformin - adverse effects | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Venoms - administration & dosage | Female | Metformin - administration & dosage | Hypoglycemia - chemically induced | Meals | Receptors, Glucagon - agonists | Drug Administration Schedule | Venoms - adverse effects | Insulin - administration & dosage | Treatment Outcome | Insulin Lispro - administration & dosage | Blood Glucose - drug effects | Insulin, Long-Acting - adverse effects | Diabetes Mellitus, Type 2 - blood | Insulin, Long-Acting - administration & dosage | Glucagon-Like Peptide-1 Receptor | Insulin Glargine | Insulin Lispro - adverse effects | Quality of Life | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Insulin - adverse effects | Peptides - adverse effects | Type 2 diabetes | Care and treatment | Dosage and administration | Hypoglycemia | Insulin | Weight gain | Health aspects | Risk factors | Diabetes | Glucose | Medical treatment | Quality of life | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
by Holman, Rury R and Bethel, M. Angelyn and Mentz, Robert J and Thompson, Vivian P and Lokhnygina, Yuliya and Buse, John B and Chan, Juliana C and Choi, Jasmine and Gustavson, Stephanie M and Iqbal, Nayyar and Maggioni, Aldo P and Marso, Steven P and Öhman, Peter and Pagidipati, Neha J and Poulter, Neil and Ramachandran, Ambady and Zinman, Bernard and Hernandez, Adrian F and EXSCEL Study Grp and EXSCEL Study Group
The New England Journal of Medicine, ISSN 0028-4793, 09/2017, Volume 377, Issue 13, pp. 1228 - 1239
This trial, which compared once-weekly exenatide plus usual care with usual care alone in patients with type 2 diabetes with or without previous cardiovascular... 
MEDICINE, GENERAL & INTERNAL | RISK | EVENT LOWERING EXSCEL | GLUCOSE CONTROL | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Exenatide | Peptides - administration & dosage | Incidence | Cardiovascular Diseases - complications | Hypoglycemic Agents - administration & dosage | Injections, Subcutaneous | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Venoms - administration & dosage | Female | Diabetes Mellitus, Type 2 - complications | Double-Blind Method | Drug Administration Schedule | Venoms - adverse effects | Kaplan-Meier Estimate | Diabetes Mellitus, Type 2 - blood | Least-Squares Analysis | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Peptides - adverse effects | Type 2 diabetes | Usage | Patient outcomes | Outcome and process assessment (Health Care) | Reports | Dosage and administration | Drug therapy | Observations | Myocardial infarction | Cerebral infarction | Diabetes mellitus | Pancreatitis | Amylin | Cardiovascular disease | Patients | Thyroid carcinoma | Studies | Side effects | Pancreatic carcinoma | Pancreatic cancer | Diabetes | Health risk assessment | Heart diseases | Endocrinology | Pharmaceuticals | Index Medicus | Abridged Index Medicus | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Cardioprotective Effects of Exenatide in Patients With ST-Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of Exenatide Myocardial Protection in Revascularization Study
by Woo, Jong Shin and Kim, Weon and Ha, Sang Jin and Kim, Jin Bae and Kim, Soo-Joong and Kim, Woo-Shik and Seon, Hyun Ju and Kim, Kwon Sam
Arteriosclerosis, Thrombosis, and Vascular Biology, ISSN 1079-5642, 09/2013, Volume 33, Issue 9, pp. 2252 - 2260
OBJECTIVE—Experimental evidence suggests that exenatide, a glucagon-like peptide 1 receptor analogue, has significant cardiovascular protective effects in... 
magnetic resonance imaging | percutaneous coronary intervention | reperfusion injury | myocardial infarction | exenatide | SURVIVAL | RAT | HEART-FAILURE | SIZE | ISCHEMIA | GLUCAGON-LIKE PEPTIDE-1 | PERIPHERAL VASCULAR DISEASE | DYSFUNCTION | HEMATOLOGY | STRAIN | OCCLUSION | Myocardial Infarction - blood | Predictive Value of Tests | Prospective Studies | Humans | Middle Aged | Myocardial Contraction - drug effects | Male | Peptides - administration & dosage | Troponin I - blood | Cardiotonic Agents - therapeutic use | Myocardial Infarction - therapy | Hypoglycemic Agents - administration & dosage | Time Factors | Cardiotonic Agents - adverse effects | Injections, Subcutaneous | Myocardial Infarction - pathology | Echocardiography, Doppler | Venoms - administration & dosage | Female | Myocardial Infarction - physiopathology | Republic of Korea | Hypoglycemic Agents - therapeutic use | Drug Administration Schedule | Venoms - adverse effects | Ventricular Function, Left - drug effects | Proportional Hazards Models | Stroke Volume - drug effects | Myocardium - pathology | Treatment Outcome | Biomarkers - blood | Chi-Square Distribution | Magnetic Resonance Imaging | Myocardium - enzymology | Cardiotonic Agents - administration & dosage | Venoms - therapeutic use | Creatine Kinase, MB Form - blood | Aged | Hypoglycemic Agents - adverse effects | Percutaneous Coronary Intervention - adverse effects | Peptides - adverse effects | Peptides - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial
by Ahmann, AJ and Capehorn, M and Charpentier, G and Dotta, F and Henkel, E and Lingvay, I and Holst, AG and Annett, MP and Aroda, VR
DIABETES CARE, ISSN 0149-5992, 02/2018, Volume 41, Issue 2, pp. 258 - 266
OBJECTIVE To compare the efficacy and safety of once-weekly semaglutide 1.0 mg s.c. with exenatide extended release (ER) 2.0 mg s.c. in subjects with type 2... 
METFORMIN | PEPTIDE-1 PROMOTES SATIETY | PIOGLITAZONE | LIRAGLUTIDE | SITAGLIPTIN | ENDOCRINOLOGY & METABOLISM | WEIGHT-LOSS | DOUBLE-BLIND | GLP-1 ANALOG | MELLITUS | ASSOCIATION | Glucagon-Like Peptides - administration & dosage | Humans | Middle Aged | Glycated Hemoglobin A - drug effects | Body Weight - drug effects | Male | Exenatide | Peptides - administration & dosage | Delayed-Action Preparations - administration & dosage | Young Adult | Hypoglycemic Agents - administration & dosage | Aged, 80 and over | Venoms - administration & dosage | Adult | Female | Metformin - administration & dosage | Drug Administration Schedule | Venoms - adverse effects | Treatment Outcome | Blood Glucose - drug effects | Glucagon-Like Peptides - adverse effects | Diabetes Mellitus, Type 2 - blood | Delayed-Action Preparations - adverse effects | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Peptides - adverse effects | Type 2 diabetes | Clinical trials | Treatment outcome | Care and treatment | Analysis | Drugs | Randomization | Diabetes mellitus | Body weight | Safety engineering | Weight reduction | Research design | Diabetes | Safety | Drug therapy | Diabetes mellitus (non-insulin dependent) | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Exenatide and the treatment of patients with Parkinson's disease
by Aviles-Olmos, Iciar and Dickson, John and Kefalopoulou, Zinovia and Djamshidian, Atbin and Ell, Peter and Soderlund, Therese and Whitton, Peter and Wyse, Richard and Isaacs, Tom and Lees, Andrew and Limousin, Patricia and Foltynie, Thomas
Journal of Clinical Investigation, ISSN 0021-9738, 06/2013, Volume 123, Issue 6, pp. 2730 - 2736
Background. There is increasing interest in methods to more rapidly and cost-efficiently investigate drugs that are approved for clinical use in the treatment... 
MEDICINE, RESEARCH & EXPERIMENTAL | RODENT MODELS | GLYCEMIC CONTROL | GLUCAGON-LIKE PEPTIDE-1 | CLINICAL-TRIAL | EXENDIN-4 | RECEPTOR | ANIMAL-MODEL | RANDOMIZED CONTROLLED-TRIAL | DOPAMINERGIC-NEURONS | TREATED PATIENTS | Off-Label Use | Venoms - adverse effects | Humans | Middle Aged | Motor Activity - drug effects | Male | Parkinson Disease - drug therapy | Drug Repositioning | Weight Loss - drug effects | Parkinson Disease - physiopathology | Antiparkinson Agents - adverse effects | Disease Progression | Peptides - administration & dosage | Constipation - chemically induced | Hypoglycemic Agents - administration & dosage | Injections, Subcutaneous | Venoms - administration & dosage | Female | Aged | Antiparkinson Agents - administration & dosage | Hypoglycemic Agents - adverse effects | Peptides - adverse effects | Complications and side effects | Dosage and administration | Parkinson's disease | Research | Drug therapy | Exenatide | Studies | Biomedical research | Parkinsons disease | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights